Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $2.48 Million - $7.41 Million
175,000 New
175,000 $7.2 Million
Q2 2020

Aug 14, 2020

SELL
$29.88 - $56.74 $1.2 Million - $2.27 Million
-40,000 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$33.0 - $54.5 $1.32 Million - $2.18 Million
40,000 New
40,000 $1.61 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Integral Health Asset Management, LLC Portfolio

Follow Integral Health Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Integral Health Asset Management, LLC with notifications on news.